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Abstract
Metformin hydrochloride tablet is a drug of choice in the treatment of diabetes mellitus type-2 especially in 
obese patients. It is normally given in initial doses of 500 mg tablet two or three times daily or 850 mg once 
or twice daily with or after meals. Recently there were numerous concerns on the increase in substandard 
pharmaceutical products on the market. A study was therefore carried out to determine the potency of some 
brands of metformin hydrochloride tablet BP 500 mg using the test method for assay as prescribed in the 
British Pharmacopoeia (BP) monograph. In the study, seven different brands of sample were purchased 
from various pharmacies in Accra and analyzed. The results indicated that all the samples analyzed passed 
the test for assay, dissolution rate and uniformity of weight. It is recommended that a study be carried out 
on other brands.
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1. Introduction
Metformin hydrochloride tablet is an biguanide anti-diabetic. It is taken orally in the treatment of Type-2 
Diabetes Mellitus and it is a drug of first choice in obese patients. The initial dosage is 500 mg two or three 
times daily or 850 mg once or twice daily with or after meals, gradually increased if necessary to 2 to 3 g 
daily dose (Shashank, 2005). 
Metformin hydrochloride is slowly and incompletely absorbed from the gastrointestinal tract. The absolute 
bioavailability of a single 500 mg dose is reported to be about 50 to 60 % although this is reduced 
somewhat if taken with food. Once absorbed, plasma binding is negligible, and it is excreted unchanged in 
the urine. The plasma elimination half-life is reported to range from about 2 to 6 hours after oral doses. 
Diabetes mellitus type-2 is a metabolic disorder that is characterized by high blood glucose in the context of 
insulin resistance and relative insulin deficiency ( Jayasagar et al. 2002 ). This is in contrast to diabetes 
mellitus type-1, in which there is an absolute insulin deficiency due to the destruction of islet cells in the 
pancreas. The classic symptoms are excessive thirst, frequent urination and constant hunger. Type-2 
diabetes makes up about 90% of cases of diabetes with the other 10% primarily due to diabetes mellitus 
type-1 and gestational diabetes.
Following alerts by the Food and Drugs Authority (FDA) of Ghana on the presence of fake drugs, including 
some from the producers of metformin on the market on 13th of February 2013, it become necessary to 
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carry out an assessment of the potency (label claim) of Metformin hydrochloride 500 mg tablets sold in 
pharmacy shops in order to ascertain their potency.
1.1 Problem statement
Counterfeit and substandard medicines have been a serious problem facing health delivery systems
developing countries. The quality of metformin hydrochloride BP 500 mg as a substandard  drug or a fake 
is of great importance on the Ghana. 
By some estimation, about 40-60% of medicines on the market are fake or substandard. Several efforts 
have been both proposed and undertaken to combat the problem. Systematically assaying the  various 
drugs  on the  market  will expose the fake  and  substandard  ones.
1.2 Objectives
The objective was to carry out Assay, Dissolution Rate and Weight Uniformity of metformin hydrochloride 
tablet BP 500 mg, and compare it to the British Pharmacopoeia (BP) standards to determine their potency  
or  otherwise.
2. Metformin
Metformin is an oral anti-diabetic drug in the biguanide class. It is the first- line drug of choice for the 
treatment of type-2 diabetes, in particularly, in overweight and obese people and those with normal kidney 
function. Metformin is the only anti diabetic drug that has been conclusively shown to prevent the 
cardiovascular complications of diabetes. It helps to reduce LDL cholesterol and triglyceride levels, and is 
not associated with weight gain. As of 2010, metformin is one of the only two anti diabetic drugs in the 
World Health Organization model list of essential medicines (WHO, 2010).
When prescribed correctly, metformin causes few adverse effects (the most common is gastrointestinal 
upset) and is associated with a low risk of hypoglycemia. First synthesized and found to reduce blood sugar 
in the 1920’s, metformin was forgotten for the next two decades as research shifted to insulin and other 
anti-diabetics. Interest in metformin was rekindled in the late 1940’s after several reports that it could 
reduce blood sugar levels in people, and in 1957, French physician Jean Sterne published the first chemical 
trial of metformin as a treatment for diabetes. Metformin is now believed to be the most widely prescribed 
anti-diabetic drug in the world (Bailey, 2004).
2.1 Medical Uses of Metformin
Metformin is primarily used for type-2 diabetes, but it is increasingly being used in Polycystic Ovary 
Syndrome (PCOS), and non-alcoholic Fatty Liver Disease, NAFLD (Marchesini et al., 2001). The benefit 
of metformin in NAFLD has not been extensively studied and may only be temporary (Nair et al., 2004).
2.1.1 Type-2 Diabetes
Over 10  years of treatment in a study group, metformin reduced diabetes complications and  overall 
mortality by 30% when compared with insulin and sulfonylurea (glibenclamide and chlorpropamide) and 
by about 40% when compared with the group only given dietary advice. 
Metformin affords a good level of blood sugar control to insulin and sulfonylurea, it appears to decrease 
mortality primarily through decreasing heart attacks, strokes and other cardiovascular complications (Selvin 
et al., 2007 ).
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2.1.2 Pre-Diabetes
Metformin treatment for people at risk for type-2 diabetes may decrease their chances of developing the 
disease, although intensive physical exercise and dieting work significantly better for this purpose. In a  
study in the United States known as Diabetes Preventive Program, participants were divided into groups 
and were either placed on metformin or lifestyle intervention, and they were observed for an average of 
three years. The intensive program of lifestyle modification included a 16-lesson training on dieting and 
exercise followed by monthly individualized sessions with the goals to decrease the body weight by 7% and 
engage in a physical activity for at least 150 minutes per week. The incidence of diabetes was 58% lower in 
the lifestyle group and 31% lower in those given metformin. Among younger people with a higher body 
mass index lifestyle modification was no more effective than metformin, and for older individuals with a 
lower body mass index, metformin was no better than placebo in preventing diabetes. After 10 years, the 
incidence of diabetes was 34% lower in the group of participants given diet and exercise and 18% lower in 
those given metformin ( Knowler et al., 2009 ).
It  is unclear whether metformin slowed down the progression of pre-diabetes to diabetes (true preventive 
effect), or the decrease of diabetes in treated population was simply due to its glucose-lowering action (
treatment effect ) (Lilly, 2009).
3. Materials and Methods
3.1 Sampling
Seven different brands of metformin hydrochloride 500 mg BP Tablets were purchased from different 
pharmacy shops in Accra.
3.2 Procedures
Reference Procedure: (British Pharmacopoeia, 2010)
3.2.1 Assay
Twenty  tablets were weighed and grounded into powder.  An amount of 0.1 g of the powdered  metformin 
hydrochloride was  added  to 70 ml  of water  and  shaken  for  15 minutes. The suspension  was  further  
diluted to 100 ml with water and  filtered. 20 ml  of the resulting  solution was  discarded  after settling and 
10 ml of the resulting solution  again diluted  to 100 ml. The absorbance of the final solution was measured 
at a wavelength  of  232 nm using the  ultraviolet- visible spectrophotometer .
The  content of  metformin hydrochloride was then  computed taking  798 as  the value of A (1%, 1cm) at  a 
peak  of 232 nm.
The expression A (1%, 1cm) representing the specific absorbance of a dissolved substance refers to the 
absorbance of 1% w/v solution in a 1 cm cell and measured at a defined wavelength such that;
                                                                 A (1%, 1cm) = 10ε/M
Where M is the molecular weight of the substance being examined.
The specific absorbance is therefore the nominal absorbance of a 1cm layer of a 1% w/v solution of the 
absorbing solute.
3.2.2 Tablet Dissolution Rate
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Six tablets were selected randomly from a brand, weighed and placed in the dissolution basket and lowered 
into a medium (900 ml of 0.68 % w/v solution of potassium di-hydrogen orthophosphate, pH 6.8). The 
chamber was then operated at 100 rpm for 45 minutes, after which a sample of the resulting solution was 
drawn separately from each chamber and filtered, 10 ml of the filtrate was then diluted to 100 ml. The 
absorbance of the filtered solutions was then determined at the peak wavelength of 233 nm using the 
ultraviolet-visible spectrophotometer. The total content of metformin hydrochloride in the medium was 
determined using 806 as the value of A (1%, 1cm) at the peak at 233 nm.
3.2.3 Weight Uniformity
Twenty tablets  of each  brand  was  selected  randomly and weighed. The average weight was then 
evaluated,  acceptable deviations  are  not  to be more than  5 %.
4.Results And Discussions
4.1Assay
Table 1gives the distribution of the metformin hydrochloride content of samples of the various brands used 
in the study. Generally, all samples analyzed fall within the acceptable limit of 95 % ~105 % assay. Assay 
is a single test carried out for the purpose of estimating the potency of a material/preparation or the pooled 
results of two or more such tests (BP, 2010).
4.2 Dissolution
Generally, all the samples passed the test for dissolution rate which should not be less than 85%. These 
recorded (table 2) values within the recommended values according to the British Pharmacopeia (BP 
2010).
In the Pharmaceutical industry, drug dissolution testing is routinely used to provide critical in vitro drug 
release information for both quality control purposes, [ to assess the batch-to-batch consistency of solid oral 
dosage forms such as tablets, and drug development,] to predict in vivo drug release profiles (Bai et al.,
2011). In vitro drug dissolution data generated from dissolution testing experiments can be related to in 
vivo pharmaco-kinetic data by means of in vitro-in vivo correlations (IVIVC).
A well established predictive IVIVC model can be very helpful for drug formulation design and port-
approval manufacturing changes (Kortejarvi et al., 2006). The main objective of developing and evaluating 
an IVIVC is to establish the dissolution test as a surrogate for human bioequivalence studies, as stated by 
the Food and Drugs Administration (FDA). Analytical data from drug dissolution testing are sufficient in 
many cases to establish safety and efficacy of a design product without in vivo tests, following minor 
formulation and manufacturing changes (Qureshi, 2001).
4.3 Weight Uniformity
When 20 individuals units are taken at random and weighed, not more than two of the individual masses 
should deviate from the average mass by more than 5 % for  250 mg and above  tablets (BP 2010),
Generally, all samples passed  the test for Uniformity of Weights (Table 3).
5.Conclusion
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Inferential analysis of the analytical results proves that many brands (as sampled in the study) of metformin 
hydrochloride 500 mg tablet sold in various pharmacies in Accra are potent in terms of label claim, 
dissolution rate and uniformity in weight. This could be as a result of; the effective surveillance activities of 
the Food and Drugs Authority of Ghana, the proper storage of these medicines by wholesalers, retailers and 
pharmacies who stock these medicines, and the relatively stable nature of metformin hydrochloride 
compound.
These results are based on the laboratory analysis carried out on seven (7) brands of metformin 
hydrochloride 500 mg tablet B.P obtained from various pharmacies in Accra, namely; GLUCOPHAGE 
Tablet, METFORMIN-DENK Tablet, KINAMET 500 mg Tablet, METFORMIN 500 mg Tablet, 
DIABETMIN Tablet, GR-METFRORMIN, and BGMET Tablet.
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Table 1:Potency (Label claim) of metformin hydrochloride tablet 500mg
Name of Sample Manufacturer Batch Number Expiry Date Potency (Label 
claim) (%)
GLUCOPHAGE Merck Sante s.a.s 102841 February 2016 100.63
METFORMIN-DENK Denk Pharma GmbH & 
Co. 8MI January 2016 99.96
KINAMET Kinapharma Ltd 810 June 2016 99.96
METFORMIN-500 Bristol Labs Ltd BUH032088 May 2016 99.01
DIABEMET Hovid  Pharma BC12657 December 2015 99.01
GR-METFORMIN GR Industries Ltd MF121204 November 2015 97.34
BGMET Bliss GVS Pharma Ltd BG-112 November 2013 97.25
Table 2: Dissolution Rate of metformin hydrochloride tablet 500mg
Name of Sample Manufacturer Batch Number Expiry Date Dissolution 
Rate (%)
METFORMIN-
DENK
Denk Pharma GmbH 8MI January 2016 98.2
DIABEMET Hovid  Pharma BC12657 December 2015 98.0
GLUCOPHAGE Merck Sante s.a.s 102841 February 2016 96.5
BGMET Bliss GVS Pharma Ltd BG-112 November 2013 96.4
GR-METFORMIN GR Industries Ltd MF121204 November 2015 96.2
METFORMIN-500
Bristol Labs Ltd BUH032088 May 2016 96.0
KINAMET Kinapharma Ltd 810 June 2016 92.4
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Table 3: Weight Uniformity of metformin hydrochloride tablet 500mg
Name of Sample Manufacturer Batch 
Number
Expiry Date Weight 
Uniformity
METFORMIN-
DENK
Denk Pharma GmbH 8MI January 2016 -2.2 % ~ +1.4%
DIABEMET Hovid  Pharma BC12657 December 2015 -1.6% ~ +1.2 %
GLUCOPHAGE Merck Sante s.a.s 102841 February 2016 -0.9% ~ +1.1%
BGMET Bliss GVS Pharma Ltd BG-112 November 2013 -1.6% ~ +1.4%
GR-METFORMIN GR Industries Ltd MF121204 November 2015 -2.2% ~ +2.6%
METFORMIN-500
Bristol Labs Ltd BUH032088 May 2016 -2.0% ~ +2.6%
KINAMET Kinapharma Ltd 810 June 2016 -2.9% ~ +2.8%
